XENE
Xenon Pharmaceuticals Inc.
Key Financials
Operating Income
$-373070000
↓ 33.6%
Revenue
$311000
↑ 1843.8%
Net Income
$-345910000
↓ 47.6%
Total Liabilities
$51.4M
↑ 18.9%
EPS (Diluted)
$-4.36
↓ 44.9%
Total Assets
$633.2M
↓ 20.7%
Cash & Equivalents
$199.2M
↑ 39.6%
Long-term Debt
$10.9M
0.0%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 8/13/2026 | View on SEC |
| 144 | 8/13/2026 | View on SEC |
| SCHEDULE 13G/A | 8/13/2026 | View on SEC |
| SCHEDULE 13G/A | 8/7/2026 | View on SEC |
| 10-Q | 8/6/2026 | View on SEC |
| 8-K | 8/6/2026 | View on SEC |
| SCHEDULE 13G/A | 8/6/2026 | View on SEC |
| 4 | 6/8/2026 | View on SEC |
| 4 | 6/8/2026 | View on SEC |
| 144 | 6/5/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | XENE |
| Company Name | Xenon Pharmaceuticals Inc. |
| CIK | 1582313 |
| Sector | Pharmaceutical Preparations |
| Industry | Large accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | A1 |
| Phone | (604) 484-3300 |